cRGDwV

cRGDwV is a cyclic Arg-Gly-Asp (RGD) peptide derivative containing aromatic amino acids. It has demonstrated inhibitory effects on non-small cell lung cancer (NSCLC) cell growth, TGF-β1-induced epithelial-to-mesenchymal transition (EMT), and invasion. These effects have been observed particularly in gefitinib-resistant NSCLC A549 (A549GR) cells, where cRGDwV also inhibits mesenchymal marker expression, migration, and invasion. As a cyclic RGD peptide, its mechanism of action is likely through binding to integrin receptors, thereby modulating cell adhesion and signaling pathways involved in cancer progression and resistance.